|
Designations:
|
T98G [T98-G]
|
|
Depositors:
|
GH Stein
|
|
Biosafety Level:
|
1
|
|
Shipped:
|
frozen
|
|
Medium & Serum:
|
See Propagation
|
|
Growth Properties:
|
adherent
|
|
Organism:
|
Homo sapiens (human)
|
|
Morphology:
|
fibroblast
|
|
Source:
|
Organ: brain
Disease: glioblastoma multiforme
|
|
Permits/Forms:
|
In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.
|
|
CRL-1690 T98G [T98-G] 人多形性惡性膠質(zhì)瘤細胞
|
|
Applications:
|
transfection host
|
|
Tumorigenic:
|
No
|
|
DNA Profile (STR):
|
Amelogenin: X,Y
CSF1PO: 10,12
D13S317: 13
D16S539: 13
D5S818: 10,12
D7S820: 9,10
THO1: 7,9.3
TPOX: 8
vWA: 17,20
|
|
Cytogenetic Analysis:
|
This is a human cell line with hyperpentaploid chromosome count. The modal chromosome number should be around 128 to 132. The rate of cells with higher ploidies was 1.39%. Fourteen to 16 marker chromosomes were common to most cells. They were: der(1)t(1;?) (p36;?), i(6p), der(10)t(10;?) (q24;?), der (19)t(19;?) (q13;?), der(15)t(15;?) (q26?;?), minute metacentric and eight to ten others. Most of these structurally altered markers had complex interchromosomal exchanges. The der(10) and der(19) could be formed from a balanced translocation, i.e., t(10;19) (q24;q13). These two markers and the minute metacentric were present in three or more copies in most cells. There were six or more copies for N5, N7, N11, N13, N20, N21, and N22 in most cells. The X and N15 had only one copy.
|
|
Age:
|
61 years
|
|
Gender:
|
male
|
|
Ethnicity:
|
Caucasian
|
|
Comments:
|
When deprived of serum or when crowded, the cells enter a viable G1 arrested state.
The cells are anchorage independent.
|
|
Propagation:
|
ATCC complete growth medium: The base medium for this cell line is ATCC-formulated Eagle's Minimum Essential Medium, Catalog No. 30-2003. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Temperature: 37.0°C
|
|
Subculturing:
|
Protocol: Volumes used in this protocol are for 75 sq cm flasks; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
-
Remove and discard culture medium.
-
Briefly rinse the cell layer with Ca++/Mg++ free Dulbecco's phosphate-buffered saline (D-PBS) or 0.25% (w/v) Trypsin - 0.53 mM EDTA solution to remove all traces of serum which contains trypsin inhibitor.
-
Add 2.0 to 3.0 ml of Trypsin-EDTA solution to flask and observe cells under an inverted microscope until cell layer is dispersed (usually within 5 to 15 minutes).
Note: To avoid clumping do not agitate the cells by hitting or shaking the flask while waiting for the cells to detach. Cells that are difficult to detach may be placed at 37C to facilitate dispersal.
-
Add 2.0 to 3.0 ml of complete growth medium and aspirate cells by gently pipetting
-
Resuspend the cell pellet in fresh growth medium. Add appropriate aliquots of the cell suspension to new culture vessels.
-
Incubate cultures at 37C.
Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:10 is recommended
Medium Renewal: 2 to 3 times per week
|
|
Preservation:
|
Freeze medium: Complete growth medium 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase
|
|
Related Products:
|
Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2003
recommended serum:ATCC 30-2020
|
|
References:
|
22322: Stein GH. T98G: an anchorage-independent human tumor cell line that exhibits stationary phase G1 arrest in vitro. J. Cell. Physiol. 99: 43-54, 1979. PubMed: 222778
23094: Olopade OI, et al. Molecular analysis of deletions of the short arm of chromosome 9 in human gliomas. Cancer Res. 52: 2523-2529, 1992. PubMed: 1568221
32287: Rostomily RC, et al. expression of neurogenic basic helix-loop-helix genes in primitive neuroectodermal tumors. Cancer Res. 57: 3526-3531, 1997. PubMed: 9270024
|
